Optimally, control methods would be applicable to all poultry and be safe, cost effective, and efficacious. Current research regarding novel MG vaccines is addressed herein.
DESCRIPTION OF PROBLEM
Mycoplasma gallisepticum (MG) is a major pathogen of gallineaceous and certain nongallineaceous avian species [1, 2] . This highly transmissible organism is the etiologic agent of chronic respiratory disease in chickens and infectious sinusitis in turkeys. Clinical symptoms of MG infections in these avian species include 1 To whom correspondence should be addressed: jdevans@msa-msstate.ars.usda.gov. rales, coughing, nasal discharge, sinusitis, and severe air sac lesions, and consequences of MG include mortality, carcass condemnation, and reduced egg production, hatchability, feed efficiency, and weight gain [2, 3, 4, 5, 6] . Due to the substantial performance and production losses, MG has been described as the most economically important of the 4 pathogenic Mycoplasma species affecting poultry, which also in-clude Mycoplasma synoviae (chicken and turkey pathogen), Mycoplasma synoviae (turkey pathogen), and Mycoplasma meleagridis (turkey pathogen) [5, 7, 8] . The annual economic impact of MG infections in the United States was estimated at between $118 and $150 million for the layer industry alone in 1994 [4] .
In the recent past, the MG outbreaks have yielded significant losses to the poultry industry [2, 9] . Major outbreaks of MG-induced disease have been reported in North Carolina [10] . In addition, the National Poultry Improvement Plan reported [11] that among US breeding flocks between September 1999 and August 2000, field strains of MG were among mycoplasmas diagnosed in flocks totaling 11 egg-type flocks, 34 meat-type flocks, and 22 turkey flocks. These flocks were conservatively estimated to average 20,000 birds and resulted in significant economic losses to these industries. Furthermore, significant losses have also been realized by MG breaks in other sectors of the poultry industry. For example, one North Carolina broiler company stated that losses over a 6-mo period in 1999 attributable to MG were conservatively estimated to be $500,000 to $750,000 [11] .
MYCOPLASMA GALLISEPTICUM PATHOGENESIS
Although MG affects poultry industries worldwide [12] , its pathogenesis toward avian species is not well understood [13, 14, 15, 16, 17] . Research has indicated that attachment of MG to specific target cells via sialic acid residues along the respiratory epithelium is required prior to initiation of the disease processes and that a complex multifactorial process mediates cytadherence [16, 18] .
The pathogenesis of MG is complicated by an organism's ability to alter its antigenic profile and thereby evade the host's immune system [19] . Multiple membrane proteins and lipoproteins have been characterized with size-or phase-variant forms that occur at high frequency and confer phenotypic or antigenic variation to MG. These proteins and lipoproteins include PvpA [20, 21] and pMGA (also termed vlhA [22] ) proteins [23, 24] . Additionally, at least 3 other membrane proteins have been identified as phase variant [21] . The pathogenicity of MG may be further complicated by the ability of MG to penetrate and survive within host cells resulting in dissemination throughout the host [14] . Cumulatively, these factors may result in chronic infection of the host [25, 26] .
CURRENT MG CONTROL STRATEGIES
Current control practices against MG infection in the United States include intense biosecurity and biosurveillance via serological monitoring of flocks, MG isolation techniques, and DNA-based detection methods [2, 27] . Although antibiotics are commonly used to reduce the effects of MG infections, they have proven ineffective at clearing MG infections [7] . Biosecurity and biosurveillance measures have been largely successful at minimizing MG outbreaks among the breeding stock of the turkey and chicken industries, in which outbreaks occur only in a sporadic nature. Furthermore, the "all in-all out" nature of the meat-type turkey and broiler industries allows for complete eradication of infected flocks. In marked contrast, MG occurrence within the US table egg industry may be considered endemic, infecting the majority of the 276.1 million egg-type laying hens and occurring in greater than 50% of all egg laying facilities [28] . Within this sector of the industry, eradication of infected flocks is not feasible due to the extreme size (>1 million birds) and multiage nature of the complexes. The MG-infected egg-laying facilities are considered infected for life and may serve as reservoirs of infection endangering other poultry facilities of close proximity.
Because of the unique structure of the layer industry, an alternative approach has been developed to control MG infections in the United States via live attenuated MG vaccines [29] . There are currently 3 live MG vaccines approved and commercially available including F strain (FVAX-MG, Schering-Plough Animal Health), 6/85 (Mycovac-L, Intervet Inc.), and ts-11 (MG vaccine, Merial Select). Although each is distinct, varying in pathogenicity, protection afforded, and transmissibility [30] , each has been shown to effectively reduce losses associated with MG field strain challenge [6, 31, 32, 33] . The F strain was the first available attenuated live MG vaccine and has been described as the most economic in terms of initial cost and application-associated labor [34] . The F strain is capa-ble of displacing MG field strains [1] and inducing a protective immune response in the vaccinated host [35] . The F strain colonizes the respiratory tract and persists for the life of the animal. Research has demonstrated that F strain vaccination of layers limits production losses associated with MG infection (estimated at 15.7 eggs/hen per 45-wk laying cycle) by approximately 50% [6] . Interestingly, industry has demonstrated increased egg production in F strain vaccinated layers as compared with MG-clean birds [36] . Reductions in mortality [37, 38] and antibiotic requirements [36] have also been associated with F strain vaccination.
Disadvantages of F strain vaccination also exist. The F strain may induce mild upper respiratory disease, and the response may be heightened due to infection with secondary pathogens. Furthermore, the F strain is transmissible and pathogenic to turkey and meat-type chicken flocks [35, 39] . Subsequently, the 2 alternative MG vaccines, ts-11 and 6/85, were developed. They were demonstrated to be safer due to reduced transmissibility and nonpathogenicity toward turkeys and young broilers and were widely accepted in vaccination regimens. However, these strains were shown to be less protective against field strain challenge as compared with the F strain [40, 41] . Furthermore, the production effects of ts-11 and 6/85 on layers have not been conclusively evaluated.
Historically, vaccination schemes for use in the layer industry has largely involved treatment with a single vaccine. However, new vaccination technologies, more affordable vaccines, and recent MG breaks in previously vaccinated flocks have resulted in secondary vaccinations. For example, recent MG breaks in layer flocks previously vaccinated with ts-11 or 6/85 have been reported and have resulted in revaccination of these flocks by F strain [34] . Although single vaccination regimens have been widely reflected in research, the microbial and production effects of utilizing multiple vaccines on a single flock have not been adequately addressed in current research. To date, only a single study has been documented involving multiple vaccinations within a single flock. However, in this study, the flocks were treated with the F strain in 1981 and secondarily with ts-11 in 1994 [42] , which is not representative of the current vaccination schemes.
DEVELOPMENT OF NOVEL MG VACCINES
Due to the limitations of available live vaccines, alternative vaccines are being sought. Vaccines in their simplest form consist of one or more purified subunits (antigens) and are presented to the host in the presence of an adjuvant, a substance that enhances the immune response. More complex vaccine forms may include killed pathogens or bacterins presented in conjunction with an adjuvant. Research regarding the use and further development of MG subunit and bacterin vaccines has recently been reviewed, and although these vaccine types were generally protective, the application of the vaccines thus far developed may be limited due to costs associated with vaccination protocols and overall effectiveness [43] .
Novel live attenuated MG strains (similar to those currently licensed) may represent another means to control MG. Vaccines of this type present a wide array of relevant antigens to the host for immune recognition. A novel live attenuated MG vaccine strain designated K5054 is currently being evaluated for control of MG. The strain was isolated from turkeys exhibiting only mild clinical signs of MG infection. Subsequent challenge studies demonstrated that strain K5054 inoculation yielded seroconversion with very mild lesions in turkeys and protected treated birds from challenge with a virulent MG strain [44] . Further studies verified these findings in turkeys and also found strain K5054 to protect chickens from MG challenge. The strain appears to preferentially colonize the upper respiratory tract and effectively reduces airsacculitis in both of these avian species [45] . Further research may confirm this strain as a safe and effective vaccine for both turkeys and chickens. However, a possible deterrent is the potential of this and other similarly undefined attenuated strains to revert to their wild-type pathogenic counterparts.
Recent technologic advances in molecular biology have resulted in the development of vaccines utilizing live organisms to present cloned pathogenic components to the host [46] . The use of live organisms as vectors or carriers of heterologous proteins has gained particular in-terest in protecting against mucosal pathogens in which the contribution of the local mucosal response (IgA) may be important [47] . Numerous bacteria, both gram-positive and gram-negative, have been investigated as carriers of recombinant heterologous antigens, and surface display of the recombinant proteins is generally preferable to elicit a strong immune response. Attenuated and nonpathogenic bacteria may be used as vectors; however, nonpathogenic species may be preferred [46] .
Recently, molecular techniques and information applicable to MG and other closely related mycoplasma species have progressed and may be applied to recombinant vaccine development for MG. These new molecular advancements include the development of transformation and expression strategies and the identification and cloning of important MG colonization factors and surface antigens. Gene transfer, which is complicated by potent endonucleases [48] , has been accomplished in mycoplasma species via electroporation [49, 50, 51] , polyethyleneglycolmediated transformation [18, 52, 53] , and Enterococcus faecalis-mediated conjugation [54] . The transposons Tn916, Tn4001, and derivatives have proven functional in mycoplasmas [49, 50, 53, 55, 56] and may be applied to mutant construction, gene expression, protein function analysis, and cellular tagging [48] . The MG expression studies completed to date include the use of a LacZ fusion protein [57] and a wild type GapA [18] . In addition, multiple genes encoding surface antigens and putative colonization factors have been cloned and characterized. These include gapA [16] , pvpA [20, 21] [18] , and multiple members of the pMGA gene family [24, 59, 60, 61] (also termed vlhA [22] ). Although the use of some of these genes in a recombinant vaccine strain would be complicated by variable expression, they may provide the basis of a safe and effective MG vaccine.
To this end, a recent attenuated MG strain that was generated in a laboratory and genetically modified is currently being evaluated for control of MG infections. The MG strain designated GT5 was created by genetically modifying a cytadherence-negative laboratory strain of MG (gapA, crmA, and hatA) to restore expression of the primary cytadhesin GapA [62] . The recombinant MG strain expressed GapA but did not differ in its ability to cytadhere from its cytadherence-negative parent strain. An in vivo study demonstrated that chickens vaccinated with strain GT5 and subsequently challenged with a virulent MG strain were protected from MGinduced disease. Specifically, the colonization abilities of the virulent MG strain and the infection-associated tracheal lesions were reduced [63] .
Live attenuated viruses may also serve as vehicles for expression of MG antigens for host immune recognition. To this end, a US-based company has produced a USDA-approved recombinant fowl pox virus containing genes encoding for MG antigens for use with chickens and turkeys. The product, Vectormune FP-MG, is currently being evaluated for protection against MG challenge. Data from product field trials indicate that the vaccine yields low rates of seroconversion and does not induce any MGassociated clinical signs. Further, initial field studies indicate that chickens vaccinated with Vectormune FP-MG may be protected from MG challenge [64] . However, research regarding this product is limited, and further research is necessary to determine the level of protection offered by the vaccine.
Expression of MG antigens in a nonpathogenic heterologous bacterial host may provide an alternative recombinant vaccine. Successful development of this live recombinant MG vaccine requires selection of a proper host and vector for stability, safety, and effectivity. For stability, the host and vector should be well maintained along the respiratory tract of avian species. In addition, the host and vector should be demonstrated as nonpathogenic and ideally should have a well-understood genetic system with cloning and expression methods previously developed. Unfortunately, the nonpathogenic strains that are known to commonly reside within the avian respiratory tract have poorly characterized genetic systems.
Mycoplasma gallinarum is a common isolate of avian species [65] and is currently being evaluated as a possible host/vector for MG antigen expression. It has been isolated from the respiratory and reproductive tracts of poultry [66] and is widely considered nonpathogenic [67] . Further, research has suggested a beneficial role of M. gallinarum toward its avian host. Taylor-Robinson and Cherry [68] found that colonization of tracheal ring organ cultures by M. gallinarum protected the ciliated epithelium from MG and delayed ciliostasis as compared with the untreated control. Furthermore, Branton et al. [69] observed that the onset of fatty liver hemorrhagic syndrome is delayed in M. gallinarum-inoculated birds as compared with uninfected controls. M. gallinarum elicits only a weak immune CONCLUSIONS AND APPLICATIONS [71, 72] . The potential use of M. gallinarum as a host and vector is currently limited, however, by the scarcity of information regarding the organism's genetic system, which includes only research of M. gallinarum's 16S rRNA and leucine aminopeptidase genes [73] .
